Novartis Not Nervous About SGLT2 Threat To Entresto

Cardiovascular Blockbuster Closing In On $4-$5bn Sales Guidance

The company's pharma chief Marie-France Tschudin does not expect Entresto's "unique position" in heart failure to be threatened by SGLT2 inhibitors such as Jardiance and Farxiga, saying those drugs are add-ons that will be used predominantly in diabetes patients.

frontrunner
Novartis expects Entresto to continue setting the pace in heart failure • Source: Alamy

As Novartis AG reported another very strong quarter for Entresto, the Swiss major does not think that the advent of competition from the SGLT2 inhibitor class for heart failure (HF) patients will have much effect on the cardiovascular drug's peak sales target of around $5bn.

Novartis's second quarter results unveiled on 21 July revealed that sales of Entresto (sacubitril/valsartan) soared by 46% at constant currencies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category